SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

October 05, 2010 10:22 ET

Elsevier Business Intelligence's IN3 Summit Will Offer Partnering Opportunities for Medtech Innovators With Top Investors and Corporate Acquirers in San Francisco on October 27-29, 2010

SAN FRANCISCO, CA--(Marketwire - October 5, 2010) -  Elsevier Business Intelligence, the medtech industry's leading provider of strategic business intelligence and partnership investment conferences, announced today that it will host IN3 'Medical Device' Summit on October 27-29 at The Grand Hyatt Hotel in San Francisco. IN3 Summit is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. The following panel discussions and participants are confirmed.

"What Are Corporate Buyers Looking For?"

  • David Cassak, Vice President, Content, Elsevier Business Intelligence (moderator)
  • Jeffrey J. Steinle, Sr. Director, Corporate Development, Medtronic
  • Lukas Scheibler, PhD, Vice President, R & D Alliances, Alcon Laboratories, Inc.

"What Are the Hot Deals Now and in the Future?"

  • David Cassak, Vice President, Content, Elsevier Business Intelligence (moderator)
  • John Onopchenko, Managing Director, Synergy LSP
  • Jeani Delagardelle, Managing Director, New Leaf Ventures
  • Evan Melrose, Managing Director, PTV Sciences
  • Lisa Suennen, Co-founder and Managing Member, Psilos
  • Teo Forcht Dagi, MD, MPH, Partner, HLM Venture Partners

"Changes to the 510(k) Program: New Requirements You Must Implement."

  • David Filmore, Senior Editor of "The Gray Sheet" (moderator) -- Elsevier Business Intelligence
  • Christy Foreman, Acting Director of the Office of Device Evaluation -- CDRH, FDA
  • Dr. Joshua Makower, Founder/CEO, ExploraMed, Inc.
  • Laurie Clarke, Partner, King & Spaulding, LLP

Nearly all of the emerging-company presentation program has been filled. Apply here to present at the IN3 Summit in San Francisco.

Investment firms and corporate acquirers that have attended IN3 events this year or who have registered to attend IN3 Summit include: Abingworth Management - Accuitive Medical Ventures - Advanced Technology Ventures - Aisling Capital - Alloy Ventures - Apposite Capital - Arboretum Ventures - Baird Venture Partners - Becton Dickinson - Biomed Innovation Fund - Boston Scientific - Canaan Partners - Capricorn Venture Partners - Cardinal Health - CHL Medical Partners - Covidien - Credit Agricole Private Equity - De Novo Ventures - Delphi Ventures - Delta Partners - Domain Associates - Earlybird Venture Capital - Early Stage Partners - Edmond de Rothschild Investment Partners - Essex Woodlands Health Ventures - Forbion Capital Partners - Fountain Healthcare Partners - Gilde Healthcare Partners - Hercules Technology Growth Capital - HLM Venture Partners - Hunza Ventures - Index Ventures - Kearny Venture Partners - Life Sciences Partners - Matignon Investissement & Gestion - Medtronic - MPM Capital - NBGI Ventures - New Leaf Venture Partners - Nexus Medical Partners - Pappas Ventures - Psilos - Prism Venture Partners - PTV Sciences - RCT BioVentures - Safeguard Scientifics - Seroba-Kernel Life Sciences - Seventure Partners - Siemens Venture Capital - Skyline Ventures - Smith & Nephew - Sofimac Partners - Sofinnova Partners - St. Jude Medical - Stryker Corporation - SV Life Sciences - Synergy Life Science Partners - Thomas McNerney & Partners - Trevi Health Ventures - Versant Ventures - Wellington Partners - Western Investment Fund -Ysios Capital.

Upcoming IN3 events: 1) Feb. 22-24, 2011, IN3 West 2011, Las Vegas, The Venetian Resort; 2) June 21-23, 2011, IN3 East, Boston, The Hyatt Regency; 3) Spring 2011, IN3 Europe, Location TBA. For more information about IN3 events, please contact: Kayleen Kell at +1-949-453-0071, or email K.Kell@Elsevier.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, an Elsevier company, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Elsevier Business Intelligence (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include Sciverse ScienceDirect (www.sciencedirect.com), Sciverse Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information

  • Contact:
    Ronald Trahan, APR
    Ronald Trahan Associates Inc.
    508-359-4005, x108